Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials. Ferreira PCL, Bellaver B, Povala G, Bauer-Negrini G, et al. Neurology 2026;106:e214441.

Read + Share

Amedeo Smart

Independent Medical Education

Ferreira PCL, Bellaver B, Povala G, Bauer-Negrini G, et al. Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials. Neurology 2026;106:e214441.
PMID: 41364889